FBX11 Antibody

Overview of FBXO11 and Its Antibodies

FBXO11 mediates the degradation of proteins like BCL6, DTL/CDT2, and SNAI1, influencing processes such as B-cell differentiation, TGF-β signaling, and epithelial-to-mesenchymal transition . Its dysregulation has been implicated in inflammation, antiviral responses, and erythropoiesis .

FBXO11 antibodies are polyclonal or monoclonal reagents designed to bind specifically to FBXO11, enabling its detection via techniques like Western blot (WB), immunoprecipitation (IP), and immunofluorescence (IF). Key characteristics include:

• Immunogen: Synthetic peptides or recombinant FBXO11 fusion proteins .

• Reactivity: Primarily human, with cross-reactivity reported in mouse and rat .

• Observed Molecular Weight: ~94–104 kDa .

Applications in Research

FBXO11 antibodies are validated for diverse experimental workflows, as summarized below:

Key Notes:

• WB Optimization: Dilutions vary widely; titration is recommended .

• IP Efficiency: Requires 0.5–4.0 µg antibody per 1–3 mg lysate .

• IF Specificity: Detects nuclear localization in human cell lines .

Key Research Findings

FBXO11 antibodies have been pivotal in elucidating its biological roles:

Macrophage Cell Death and Inflammation

FBXO11 regulates C5aR1 (complement receptor) and IL-1β expression in macrophages:

• C5aR1 Regulation: Loss of FBXO11 reduces C5aR1 mRNA and surface expression, protecting macrophages from Panton-Valentine leukocidin (PVL)-mediated toxicity .

• IL-1β Modulation: FBXO11 dampens IL-1β secretion post-NLRP3 activation via BCL-6-dependent pathways .

Erythropoiesis and MHC-II Regulation

• Erythroid Development: FBXO11 degrades BAHD1, a repressor of erythroid genes, promoting red blood cell maturation .

• MHC-II Expression: FBXO11 targets CIITA for degradation, modulating MHC-II levels critical for immune responses .

Antiviral and Inflammatory Pathways

• TRAF3 Ubiquitination: FBXO11 mediates Lys-63-linked ubiquitination of TRAF3, enhancing TBK1-IRF3-IFN-I signaling during antiviral responses .

Challenges in Antibody Development

• Specificity: Variability in epitope recognition necessitates rigorous validation .

• Dilution Sensitivity: WB dilutions span 1:200–1:50,000, requiring optimization .

• Batch Consistency: Lyophilized vs. liquid formats (e.g., Abbexa’s lyophilized antibody) affect storage and reconstitution .